GSK plc said it has agreed to acquire a trispecific T cell-engager from Chimagen Biosciences for the treatment of multiple myeloma. The London and New York-listed company will pay an upfront fee for full global rights to the program, with Chimagen eligible for development and commercial milestone payments. The agreement has a total potential value of up to $750 million, subject to customary closing conditions.
Chimagen is a privately held, clinical-stage biotechnology company focused on developing multi-specific T cell-engagers and NK cell-engagers. The acquired trispecific T cell-engager is designed to bind to T cells while simultaneously targeting two tumor-associated antigens. The program is expected to enter phase I trials in 2027.
Multiple myeloma is the third most common blood cancer globally, with approximately 180,000 new cases diagnosed each year. The disease is generally considered treatable but not currently curable.
The deal builds on an existing relationship between GSK and Chimagen. The companies previously agreed for GSK to acquire CMG1A46, a clinical-stage dual CD19 and CD20-targeted T cell-engager currently in phase I trials for B-cell malignancies and B-cell dependent autoimmune disorders.
Hesham Abdullah, senior vice president and global head of oncology R&D at GSK, said the deal secures a promising T cell engager and advances GSK's leadership goals in blood cancer. He said the agreement complements GSK's existing multiple myeloma portfolio by adding a potential option for patients facing the disease.
